Company / Free Cash Flow per Share
Rapport Therapeutics, Inc. Free Cash Flow per Share History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$3.24
FY2024
5-year range
-$19.14 / -$3.24
FY2023-FY2024
Trend
+83.1%
vs FY2023
Sector context
#155 of 192
Health Care
What the data says
Rapport Therapeutics, Inc.'s free cash flow per share of $-3.24 is lower than 81% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
-3.24 in FY2024.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 192This company -$3.24 Sector average -$19.84
▼
+83.7% above sector average
Key checks
Key Insights
- In FY2024, free cash flow per share increased 83.1% year-over-year.
- Ranks #155 out of 192 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 13.36 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$3.24 | +83.1% |
| FY2023 | -$19.14 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026